2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
58
Breast Neoplasms
14
Polycystic Ovary Syndrome
9
Infertility
7
Ovarian Hyperstimulation Syndrome
3
Neoplasms
3
Neoplasm Metastasis
3
Lymphoma
3
Sarcoma, Ewing
2
Sarcoma
2
Prostate Adenocarcinoma
2
Osteosarcoma
2
Uterine Anomalies
1
The Neoadjuvant Therapy
1
Sleep Wake Disorders
1
Salpingitis
1
Salivary Gland Neoplasms
1
Primary Ovarian Insufficiency
1
Pregnancy, Ectopic
1
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
1
Myofibroma
1
Metabolic Syndrome
1
Leiomyoma
1
Infertility, Female
1
Hypogonadism
1
Hodgkin Disease
1
Hematopoietic and Lymphatic System Neoplasm
1
Helping Behavior
1
Fatty Liver
1
Fatigue
1
Interventions
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Triptorelin Pamoate
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Cancer Invasive Nos
×
Triptorelin Pamoate
×
Clear all
NCT02005887
2019-05-29
TREND
ETOP IBCSG Partners Foundation
Phase 2
Completed
51 enrolled
10 charts